The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer

PPAR Research

Volumn , Issue , 2012, Pages

  Fucci, Alessandra ^a   Colangelo, Tommaso ^a   Votino, Carolina ^a   Pancione, Massimo ^a   Sabatino, Lina ^a   Colantuoni, Vittorio ^a  

^a UNIVERSITY OF SANNIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TUMOR MARKER;

CANCER THERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DISEASE SEVERITY; ESOPHAGUS CANCER; MOLECULAR MECHANICS; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 84867320451     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/242498     Document Type: Review

References (103)

1. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 5 649 688 2-s2.0-0033305213 (Pubitemid 30650602)
2. Kersten S., Wahli W., Peroxisome proliferator activated receptor agonists. EXS 2000 89 141 151 2-s2.0-0033649701
3. Michalik L., Desvergne B., Wahli W., Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Reviews Cancer 2004 4 1 61 70 2-s2.0-0347753697 (Pubitemid 38082154)
4. Evans R. M., Barish G. D., Wang Y. X., PPARs and the complex journey to obesity. Nature Medicine 2004 10 4 355 361 2-s2.0-1942518840 10.1038/nm1025 (Pubitemid 38508511)
5. Nahlé Z., PPAR trilogy from metabolism to cancer. Current Opinion in Clinical Nutrition and Metabolic Care 2004 7 4 397 402 2-s2.0-14844320128 10.1097/01.mco.0000134360.30911.bb (Pubitemid 40340645)
6. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N. A., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological Reviews 2006 58 4 726 741 2-s2.0-33751533892 10.1124/pr.58.4.5 (Pubitemid 44833742)
7. Michalik L., Wahli W., Involvement of PPAR nuclear receptors in tissue injury and wound repair. The Journal of Clinical Investigation 2006 116 3 598 606 2-s2.0-33644652740 10.1172/JCI27958 (Pubitemid 43326864)
8. Fajas L., Fruchart J. C., Auwerx J., PPAR γ 3 mRNA: a distinct PPAR γ mRNA subtype transcribed from an independent promoter. FEBS Letters 1998 438 1-2 55 60 2-s2.0-0032582349 10.1016/S0014-5793(98)01273-3 (Pubitemid 28517834)
9. Al-Shali K., Cao H., Knoers N., Hermus A. R., Tack C. J., Hegele R. A., A single-base mutation in the peroxisome proliferator-activated receptor γ 4 promoter associated with altered in vitro expression and partial lipodystrophy. The Journal of Clinical Endocrinology & Metabolism 2004 89 11 5655 5660 2-s2.0-8744247436 10.1210/jc.2004-0280 (Pubitemid 39518455)
10. Zhu Y., Alvares K., Huang Q., Rao M. S., Reddy J. K., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. Journal of Biological Chemistry 1993 268 36 26817 26820 2-s2.0-0027749599 (Pubitemid 24006385)
11. Meirhaeghe A., Amouyel P., Impact of genetic variation of PPAR γ in humans. Molecular Genetics and Metabolism 2004 83 1-2 93 102 2-s2.0-4744340732 10.1016/j.ymgme.2004.08.014 (Pubitemid 39311284)
12. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes and Development 1994 8 10 1224 1234 2-s2.0-0028180070
13. Diradourian C., Girard J., Pégorier J. P., Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 2005 87 1 33 38 2-s2.0-14544272384 10.1016/j.biochi.2004.11.010 (Pubitemid 40298763)
14. Renaud J. P., Moras D., Structural studies on nuclear receptors. Cellular and Molecular Life Sciences 2000 57 12 1748 1769 2-s2.0-0033711971
15. Mangelsdorf D. J., Evans R. M., The RXR heterodimers and orphan receptors. Cell 1995 83 6 841 850 2-s2.0-0029562554 10.1016/0092-8674(95)90200-7 (Pubitemid 26006526)
16. Berger J., Moller D. E., The mechanisms of action of PPARs. Annual Review of Medicine 2002 53 409 435 2-s2.0-0036183630 10.1146/annurev.med.53.082901. 104018 (Pubitemid 34177889)
17. Ricote M., Glass C. K., PPARs and molecular mechanisms of transrepression. Biochimica et Biophysica Acta 2007 1771 8 926 935 2-s2.0-34547603895 10.1016/j.bbalip.2007.02.013 (Pubitemid 47198544)
18. Yessoufou A., Wahli W., Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Medical Weekly 2010 140 w13071 2-s2.0-79952064509
19. Torchia J., Glass C., Rosenfeld M. G., Co-activators and co-repressors in the integration of transcriptional responses. Current Opinion in Cell Biology 1998 10 3 373 383 2-s2.0-0031835267 10.1016/S0955-0674(98)80014-8 (Pubitemid 28287049)
20. Li M., Pascual G., Glass C. K., Peroxisome proliferator-activated receptor γ -dependent repression of the inducible nitric oxide synthase gene. Molecular and Cellular Biology 2000 20 13 4699 4707 2-s2.0-0034121698 10.1128/MCB.20.13.4699-4707.2000 (Pubitemid 30396117)
21. Thomas R. M., Sobin L. H., Gastrointestinal cancer. Cancer 1995 75 1 154 170 2-s2.0-0028890359
22. Al-Taie O. H., Graf T., Illert B., Katzenberger T., Mörk H., Kraus M. R., Barthelmes H. U., Scheurlen M., Seufert J., Differential effects of PPAR γ activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. Journal of Gastroenterology 2009 44 9 919 929 2-s2.0-70349652053 10.1007/s00535-009-0086-y
23. Konturek P. C., Nikiforuk A., Kania J., Raithel M., Hahn E. G., Mühldorfer S. M., Activation of NF κ B represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPAR γ and growth factors. Digestive Diseases and Sciences 2004 49 7-8 1075 1083 2-s2.0-4444382263 10.1023/B:DDAS.0000037790.11724.70 (Pubitemid 39178068)
24. Hafner C., Reichle A., Vogt T., New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPAR γ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Current Cancer Drug Targets 2005 5 6 393 419 2-s2.0-23844552830 10.2174/1568009054863591 (Pubitemid 41176178)
25. Schoen R. E., Pinsky P. F., Weissfeld J. L., Yokochi L. A., Church T., Laiyemo A. O., Bresalier R., Andriole G. L., Buys S. S., Crawford E. D., Fouad M. N., Isaacs C., Johnson C. C., Reding D. J., O'Brien B., Carrick D. M., Wright P., Riley T. L., Purdue M. P., Izmirlian G., Kramer B. S., Miller A. B., Gohagan J. K., Prorok P. C., Berg C. D., Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. The New England Journal of Medicine 2012 366 25 2345 2357 2-s2.0-84862583882 10.1056/NEJMoa1114635
26. Hartnett L., Egan L. J., Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 2012 33 4 723 731 2-s2.0-84857577343 10.1093/carcin/bgs006
27. Huin C., Corriveau L., Bianchi A., Keller J. M., Collet P., Krémarik-Bouillaud P., Domenjoud L., Bécuwe P., Schohn H., Ménard D., Daua M., Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. The Journal of Histochemistry & Cytochemistry 2000 48 5 603 611 2-s2.0-17544387857 (Pubitemid 30233184)
28. 1 and-γ during rat embryonic development. Endocrinology 1998 139 6 2748 2754 2-s2.0-0031788318 10.1210/en.139.6.2748 (Pubitemid 28512383)
29. Kliewer S. A., Forman B. M., Blumberg B., Ong E. S., Borgmeyer U., Mangelsdorf D. J., Umesono K., Evans R. M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359 2-s2.0-0028321529 10.1073/pnas.91.15.7355 (Pubitemid 24226862)
30. Cuzzocrea S., di Paola R., Mazzon E., Genovese T., Muià C., Centorrino T., Caputi A. P., Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR- α) in the development of inflammatory bowel disease in mice. Laboratory Investigation 2004 84 12 1643 1654 2-s2.0-10044243883 10.1038/labinvest.3700185 (Pubitemid 39600571)
31. Griffioen M., Steegenga W. T., Ouwerkerk I. J. M., Peltenburg L. T. C., Jochemsen A. G., Schrier P. I., Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms. Molecular Immunology 1998 35 13 829 835 2-s2.0-0032170844 10.1016/S0161-5890(98)00074-1 (Pubitemid 28518385)
32. Watson J. D., Oster S. K., Shago M., Khosravi F., Penn L. Z., Identifying genes regulated in a Myc-dependent manner. Journal of Biological Chemistry 2002 277 40 36921 36930 2-s2.0-0037020089 10.1074/jbc.M201493200
33. Varet J., Vincent L., Mirshahi P., Pille J. V., Legrand E., Opolon P., Mishal Z., Soria J., Li H., Soria C., Fenofibrate inhibits angiogenesis in vitro and in vivo. Cellular and Molecular Life Sciences 2003 60 4 810 819 2-s2.0-0038702371 10.1007/s00018-003-2322-6 (Pubitemid 36570772)
34. Kasai T., Miyauchi K., Yokoyama T., Aihara K., Daida H., Efficacy of peroxisome proliferative activated receptor (PPAR)- α ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis 2006 188 2 274 280 2-s2.0-33748041453 10.1016/j.atherosclerosis.2005.10.047 (Pubitemid 44301133)
35. Pozzi A., Capdevila J. H., PPAR α ligands as antitumorigenic and antiangiogenic agents. PPAR Research 2008 2008 8 906542 10.1155/2008/906542
36. Martinasso G., Oraldi M., Trombetta A., Maggiora M., Bertetto O., Canuto R. A., Muzio G., Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Research 2007 2007 9 2-s2.0-37649029200 10.1155/2007/93416 93416 (Pubitemid 46609369)
37. Gizard F., Amant C., Barbier O., Bellosta S., Robillard R., Percevault F., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J. C., Torpier G., Staels B., PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. The Journal of Clinical Investigation 2005 115 11 3228 3238 2-s2.0-27644590901 10.1172/JCI22756 (Pubitemid 41567587)
38. Barger P. M., Browning A. C., Garner A. N., Kelly D. P., p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor α: a potential role in the cardiac metabolic stress response. Journal of Biological Chemistry 2001 276 48 44495 44501 2-s2.0-0035977050 10.1074/jbc.M105945200
39. Burns K. A., Vanden Heuvel J. P., Modulation of PPAR activity via phosphorylation. Biochimica et Biophysica Acta 2007 1771 8 952 960 2-s2.0-34547589477 10.1016/j.bbalip.2007.04.018 (Pubitemid 47198547)
40. Riccardi L., Mazzon E., Bruscoli S., Esposito E., Crisafulli C., Paola R. D., Caminiti R., Riccardi C., Cuzzocrea S., Peroxisome proliferator-activated receptor- α modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice. Shock 2009 31 3 308 316 2-s2.0-62449207118 10.1097/SHK.0b013e31818339e7
41. Moraes L. A., Piqueras L., Bishop-Bailey D., Peroxisome proliferator-activated receptors and inflammation. Pharmacology and Therapeutics 2006 110 3 371 385 2-s2.0-33646524699 10.1016/j.pharmthera.2005.08.007
42. Pyper S. R., Viswakarma N., Yu S., Reddy J. K., PPAR α: energy combustion, hypolipidemia, inflammation and cancer. Nuclear receptor signaling 2010 8, article e002 2-s2.0-77954987061
43. Mutoh M., Niho N., Wakabayashi K., Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biological chemistry 2006 387 4 381 385 2-s2.0-33745491465 10.1515/BC.2006.051
44. Matthiessen M. W., Pedersen G., Albrektsen T., Adamsen S., Fleckner J., Brynskov J., Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scandinavian Journal of Gastroenterology 2005 40 2 198 205 2-s2.0-13244279846 10.1080/00365520410009573 (Pubitemid 40189001)
45. Wu C. W., Yu J., Sung J. J. Y., Peroxisome proliferator-activated receptor δ and gastric cancer. Oncology Reports 2009 22 3 451 457 2-s2.0-70349316861 10.3892/or00000456
46. Peters J. M., Hollingshead H. E., Gonzalez F. J., Role of peroxisome-proliferator-activated receptor β / δ (PPAR β / δ) in gastrointestinal tract function and disease. Clinical Science 2008 115 3-4 107 127 2-s2.0-48949102050 10.1042/CS20080022
47. Varnat F., Heggeler B. B., Grisel P., Boucard N., Corthésy-Theulaz I., Wahli W., Desvergne B., PPAR β / δ regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 2006 131 2 538 553 2-s2.0-33746682493 10.1053/j.gastro.2006.05.004 (Pubitemid 44160696)
48. Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B., Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001 142 10 4195 4202 2-s2.0-0034801882 10.1210/en.142.10.4195 (Pubitemid 32907045)
49. Hollingshead H. E., Morimura K., Adachi M., Kennett M. J., Billin A. N., Willson T. M., Gonzalez F. J., Peters J. M., PPAR β / δ protects against experimental colitis through a ligand-independent mechanism. Digestive Diseases and Sciences 2007 52 11 2912 2919 2-s2.0-34848838350 10.1007/s10620-006-9644-9 (Pubitemid 47512523)
50. Takayama O., Yamamoto H., Damdinsuren B., Sugita Y., Ngan C. Y., Xu X., Tsujino T., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., Monden M., Expression of PPAR δ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. British Journal of Cancer 2006 95 7 889 895 2-s2.0-33749316388 10.1038/sj.bjc.6603343 (Pubitemid 44498105)
51. He T. C., Chan T. A., Vogelstein B., Kinzler K. W., PPAR δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999 99 3 335 345 2-s2.0-0033615352 10.1016/S0092-8674(00)81664-5 (Pubitemid 29519912)
52. Shao J., Sheng H., DuBois R. N., Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Research 2002 62 11 3282 3288 2-s2.0-0036606010 (Pubitemid 34602426)
53. He T. C., Sparks A. B., Rago C., Hermeking H., Zawel L., Da Costa L. T., Morin P. J., Vogelstein B., Kinzler K. W., Identification of c-MYC as a target of the APC pathway. Science 1998 281 5382 1509 1512 2-s2.0-0032483439 10.1126/science.281.5382.1509 (Pubitemid 28425575)
54. Wang W., Wang R., Zhang Z., Li D., Yu Y., Enhanced PPAR- γ expression may correlate with the development of Barrett's esophagus and esophageal adenocarcinoma. Oncology Research 2011 19 3-4 141 147 2-s2.0-79952390934 10.3727/096504011X12935427587849
55. Naito Y., Takagi T., Yoshikawa T., Gastrointestinal cytoprotection by PPAR γ ligands. PPAR Research 2010 2010 8 108632
56. Tselepis C., Perry I., Dawson C., Hardy R., Darnton S. J., McConkey C., Stuart R. C., Wright N., Harrison R., Jankowski J. A. Z., Tumour necrosis factor- α in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002 21 39 6071 6081 2-s2.0-18544367202 10.1038/sj.onc.1205731
57. Abdel-Latif M. M. M., O'Riordan J., Windle H. J., Carton E., Ravi N., Kelleher D., Reynolds J. V., NF- κ B activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Annals of Surgery 2004 239 4 491 500 2-s2.0-1642334954 10.1097/01.sla.0000118751.95179.c6 (Pubitemid 38372765)
58. Sato H., Ishihara S., Kawashima K., Moriyama N., Suetsugu H., Kazumori H., Okuyama T., Rumi M. A. K., Fukuda R., Nagasue N., Kinoshita Y., Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPAR γ agonists. British Journal of Cancer 2000 83 10 1394 1400 2-s2.0-0033741281
59. Kitamura S., Miyazaki Y., Hiraoka S., Toyota M., Nagasawa Y., Kondo S., Kiyohara T., Shinomura Y., Matsuzawa Y., PPAR γ inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. Biochemical and Biophysical Research Communications 1999 265 2 453 456 2-s2.0-0033584727 10.1006/bbrc.1999.1715
60. Grommes C., Landreth G. E., Heneka M. T., Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncology 2004 5 7 419 429 2-s2.0-3042815666 10.1016/S1470-2045(04)01509-8 (Pubitemid 38878045)
61. Liu S. H., Shen C. C., Yi Y. C., Tsai J. J., Wang C. C., Chueh J. T., Lin K. L., Lee T. C., Pan H. C., Sheu M. L., Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor- γ and COX-2-dependent signals. British Journal of Pharmacology 2010 160 8 1963 1972 2-s2.0-77954881040 10.1111/j.1476-5381.2010.00804.x
62. Rotte A., MacK A. F., Bhandaru M., Kempe D. S., Beier N., Scholz W., Dicks E., Pötzsch S., Kuhl D., Lang F., Pioglitazone induced gastric acid secretion. Cellular Physiology and Biochemistry 2009 24 3-4 193 200 2-s2.0-68349127297 10.1159/000233245
63. Lu J., Imamura K., Nomura S., Mafune K. I., Nakajima A., Kadowaki T., Kubota N., Terauchi Y., Ishii G., Ochiai A., Esumi H., Kaminishi M., Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice. Cancer Research 2005 65 11 4769 4774 2-s2.0-21144439861 10.1158/0008-5472.CAN-04-2293 (Pubitemid 40740814)
64. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., Ming U T., Baird S. M., Thomazy V. A., Evans R. M., Activators of the nuclear receptor PPAR γ enhance colon polyp formation. Nature Medicine 1998 4 9 1058 1061 2-s2.0-0031667938 10.1038/2042 (Pubitemid 28417339)
65. Sarraf P., Mueller E., Jones D., King F. J., DeAngelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Spiegelman B. M., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052 2-s2.0-0031671246 10.1038/2030 (Pubitemid 28417337)
66. Drori S., Girnun G. D., Tou L., Szwaya J. D., Mueller E., Kia X., Shivdasani R. A., Spiegelman B. M., Hic-5 regulates an epithelial program mediated by PPAR γ Genes and Development 2005 19 3 362 375 2-s2.0-13244291652 10.1101/gad.1240705 (Pubitemid 40189299)
67. Su W., Bush C. R., Necela B. M., Calcagno S. R., Murray N. R., Fields A. P., Thompson E. A., Differential expression, distribution, and function of PPAR- γ in the proximal and distal colon. Physiological Genomics 2007 30 3 342 353 2-s2.0-34548069753 10.1152/physiolgenomics.00042.2007 (Pubitemid 47296193)
68. Niho N., Takahashi M., Shoji Y., Takeuchi Y., Matsubara S., Sugimura T., Wakabayashi K., Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR γ ligand. Cancer Science 2003 94 11 960 964 2-s2.0-0345099451 10.1111/j.1349-7006.2003.tb01385.x (Pubitemid 37508978)
69. Sabatino L., Fucci A., Pancione M., Colantuoni V., PPARG epigenetic deregulation and Its role in colorectal tumorigenesis. PPAR Research 2012 2012 12 687492 10.1155/2012/687492
70. Sarraf P., Mueller E., Smith W. M., Wright H. M., Jennifer B K., Aaltonen L. A., De Chapelle A. L., Spiegelman B. M., Charis E., Loss-of-function mutations in PPAR γ associated with human colon cancer. Molecular Cell 1999 3 6 799 804 2-s2.0-0033152206 10.1016/S1097-2765(01)80012-5 (Pubitemid 29323058)
71. Ikezoe T., Miller C. W., Kawano S., Heaney A., Williamson E. A., Hisatake J., Green E., Hofmann W., Taguchi H., Koeffler H. P., Mutational analysis of the peroxisome proliferator-activated receptor γ in human malignancies. Cancer Research 2001 61 13 5307 5310 2-s2.0-0035394518 (Pubitemid 32681569)
72. Burgermeister E., Seger R., MAPK kinases as nucleo-cytoplasmic shuttles for PPAR γ Cell Cycle 2007 6 13 1539 1548 2-s2.0-34548289084 (Pubitemid 47327937)
73. Garcia-Bates T. M., Lehmann G. M., Simpson-Haidaris P. J., Bernstein S. H., Sime P. J., Phipps R. P., Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Research 2008 2008 18 2-s2.0-45249111574 10.1155/2008/834612 834612 (Pubitemid 351842214)
74. Thompson E. A., PPAR γ physiology and pathology in gastrointestinal epithelial cells. Molecules and Cells 2007 24 2 167 176 2-s2.0-36549051626 (Pubitemid 350177175)
75. Pancione M., Forte N., Sabatino L., Tomaselli E., Parente D., Febbraro A., Colantuoni V., Reduced β -catenin and peroxisome proliferator-activated receptor- γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Human Pathology 2009 40 5 714 725 2-s2.0-64049092259 10.1016/j.humpath.2008.08.019
76. Pancione M., Sabatino L., Fucci A., Carafa V., Nebbioso A., Forte N., Febbraro A., Parente D., Ambrosino C., Normanno N., Altucci L., Colantuoni V., Epigenetic silencing of peroxisome proliferator- activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 2010 5 12 2-s2.0-78649953952 10.1371/journal.pone.0014229 e14229
77. Sabatino L., Fucci A., Pancione M., Carafa V., Nebbioso A., Pistore C., Babbio F., Votino C., Laudanna C., Ceccarelli M., Altucci L., Bonapace I. M., Colantuoni V., UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene. In press 2-s2.0-84856138541 10.1038/onc.2012.3
78. Ogino S., Shima K., Baba Y., Nosho K., Irahara N., Kure S., Chen L., Toyoda S., Kirkner G. J., Wang Y. L., Giovannucci E. L., Fuchs C. S., Colorectal cancer expression of peroxisome proliferator-activated receptor γ (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 2009 136 4 1242 1250 2-s2.0-62949100452 10.1053/j.gastro.2008.12.048
79. Yamamoto-Furusho J. K., Pealoza-Coronel A., Sánchez-Muoz F., Barreto-Zuiga R., Dominguez-Lopez A., Peroxisome proliferator-activated receptor-gamma (PPAR- γ) expression is downregulated in patients with active ulcerative colitis. Inflammatory Bowel Diseases 2011 17 2 680 681 2-s2.0-78651299907 10.1002/ibd.21322
80. Zhang Z.-F., Yang N., Zhao G., Zhu L., Wang L.-X., Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis. PLoS One 2012 7 1 e30551 2-s2.0-84855995582 10.1371/journal.pone.0030551
81. Andersen V., Christensen J., Ernst A., Jacobsen B. A., Tjonneland A., Krarup H. B., Vogel U., Polymorphisms in NF- κ B, PXR, LXR, PPAR γ and risk of infammatory bowel disease. World Journal of Gastroenterology 2011 17 2 197 206 2-s2.0-79955756026 10.3748/wjg.v17.i2.197
82. Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., Chamaillard M., Desreumaux P., PPAR γ as a new therapeutic target in inflammatory bowel diseases. Gut 2006 55 9 1341 1349 2-s2.0-33747777758 10.1136/gut.2006.093484 (Pubitemid 44277368)
83. Turner A. M. W., Morris K. V., Controlling transcription with noncoding RNAs in mammalian cells. BioTechniques 2010 48 6 9 16 2-s2.0-77954098792 10.2144/000113442
84. Stefani G., Slack F. J., Small non-coding RNAs in animal development. Nature Reviews Molecular Cell Biology 2008 9 3 219 230 2-s2.0-39749110083 10.1038/nrm2347 (Pubitemid 351301826)
85. Filipowicz W., Bhattacharyya S. N., Sonenberg N., Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nature Reviews Genetics 2008 9 2 102 114 2-s2.0-38349169664 10.1038/nrg2290
86. Garzon R., Calin G. A., Croce C. M., MicroRNAs in cancer. Annual Review of Medicine 2009 60 167 179 2-s2.0-67650711156 10.1146/annurev.med.59.053006. 104707
87. Krutovskikh V. A., Herceg Z., Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. BioEssays 2010 32 10 894 904 2-s2.0-77957197569 10.1002/bies.201000040
88. Kida K., Nakajima M., Mohri T., Oda Y., Takagi S., Fukami T., Yokoi T., PPAR α is regulated by miR-21 and miR-27b in human liver. Pharmaceutical Research 2011 28 10 2467 2476 2-s2.0-79955716857 10.1007/s11095-011-0473-y
89. Zhou J., Wang K.-C., Wu W., Subramaniam S., Shyy J. Y.-J., Chiu J.-J., Li J. Y.-S., Chien S., MicroRNA-21 targets peroxisome proliferators-activated receptor- α in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proceedings of the National Academy of Sciences of the United States of America 2011 108 25 10355 10360 2-s2.0-79959973595 10.1073/pnas.1107052108
90. Zheng L., Lv G. C., Sheng J., Yang Y. D., Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR- α expression, a novel mechanism for the pathogenesis of NAFLD. Journal of Gastroenterology and Hepatology 2010 25 1 156 163 2-s2.0-73449136157 10.1111/j.1440-1746.2009.05949.x
91. Tong J. L., Zhang C. P., Nie F., Xu X. T., Zhu M. M., Xiao S. D., Ran Z. H., MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin- resistant human colon cancer cells. FEBS Letters 2011 585 22 3560 3568 2-s2.0-80855144808 10.1016/j.febslet.2011.10.021
92. Jennewein C., von Knethen A., Schmid T., Brüne B., MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor γ (PPAR γ) mRNA destabilization. Journal of Biological Chemistry 2010 285 16 11846 11853 2-s2.0-77951219696 10.1074/jbc.M109.066399
93. Karbiener M., Fischer C., Nowitsch S., Opriessnig P., Papak C., Ailhaud G., Dani C., Amri E. Z., Scheideler M., microRNA miR-27b impairs human adipocyte differentiation and targets PPAR γ Biochemical and Biophysical Research Communications 2009 390 2 247 251 2-s2.0-70350125874 10.1016/j.bbrc.2009.09.098
94. Kim S. Y., Kim A. Y., Lee H. W., Son Y. H., Lee G. Y., Lee J. W., Lee Y. S., Kim J. B., miR-27a is a negative regulator of adipocyte differentiation via suppressing PPAR γ expression. Biochemical and Biophysical Research Communications 2010 392 3 323 328 2-s2.0-76349089521 10.1016/j.bbrc.2010.01.012
95. Lee J.-J., Drakaki A., Iliopoulos D., Struhl K., MiR-27b targets PPAR γ toinhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. In press 2-s2.0-82055200534 10.1038/onc.2011.543
96. Lee E. K., Lee M. J., Abdelmohsen K., Kim W., Kim M. M., Srikantan S., Martindale J. L., Hutchison E. R., Kim H. H., Marasa B. S., Selimyan R., Egan J. M., Smith S. R., Fried S. K., Gorospe M., miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor γ expression. Molecular and Cellular Biology 2011 31 4 626 638 2-s2.0-79251544878 10.1128/MCB.00894-10
97. Wang J., Song Y., Zhang Y., Xiao H., Sun Q., Hou N., Guo S., Wang Y., Fan K., Zhan D., Zha L., Cao Y., Li Z., Cheng X., Zhang Y., Yang X., Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Research 2012 22 3 516 527 2-s2.0-84857791711 10.1038/cr.2011.132
98. Gatfield D., Le Martelot G., Vejnar C. E., Gerlach D., Schaad O., Fleury-Olela F., Ruskeepää A. L., Oresic M., Esau C. C., Zdobnov E. M., Schibler U., Integration of microRNA miR-122 in hepatic circadian gene expression. Genes and Development 2009 23 11 1313 1326 2-s2.0-66149167562 10.1101/gad.1781009
99. Eendebak R. J. A. H., Lucassen P. J., Fitzsimons C. P., Nuclear receptors and microRNAs: Who regulates the regulators in neural stem cells? FEBS Letters 2011 585 5 717 722 2-s2.0-79952311298 10.1016/j.febslet.2011.01.039
100. Wang X., Song X., Glass C. K., Rosenfeld M. G., The long arm of long noncoding RNAs: roles as sensors regulating gene transcriptional programs. Cold Spring Harbor Perspectives in Biology 2011 3 1, article a003756 2-s2.0-79951676375 10.1101/cshperspect.a003756
101. Nie L., Wu H.-J., Hsu J.-M., Chang S.-S., LaBaff A. M., Li C.-W., Wang Y., Hsu J. L., Hung M.-C., Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. American Journal of Translational Research 2012 4 2 127 150 2-s2.0-84860119507
102. Xu B., Gerin I., Miao H., Vu-Phan D., Johnson C. N., Xu R., Chen X. W., Cawthorn W. P., MacDougald O. A., Koenig R. J., Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity. PLoS One 2010 5 12 2-s2.0-78649955414 10.1371/journal.pone.0014199 e14199
103. Kino T., Hurt D. E., Ichijo T., Nader N., Chrousos G. P., Noncoding RNA Gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Science Signaling 2010 3 107 ra8 2-s2.0-77951638287 10.1126/scisignal.2000568